📰 Precigen News
Page 4 - Precigen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Precigen. Real-time updates on events, politics, business and more.
May 25, 2023
Investment analysts at JPMorgan Chase & Co. initiated coverage on shares of Precigen (NASDAQ:PGEN – Get Rating) in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage set a “neutral” rating on the biotechnology company’s stock. A number of other equities analysts have also issued reports on PGEN. HC […]
May 17, 2023
Precigen, Inc. (NASDAQ:PGEN – Get Rating) – Equities researchers at HC Wainwright dropped their Q2 2023 earnings per share (EPS) estimates for shares of Precigen in a research report issued to clients and investors on Thursday, May 11th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of ($0.09) per […]
May 10, 2023
– Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse™ immunotherapy in RRP demonstrated favorable safety profile and significant reduction in...
May 4, 2023
Shares of Precigen, Inc. (NASDAQ:PGEN – Get Rating) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.34 and traded as low as $1.14. Precigen shares last traded at $1.18, with a volume of 980,821 shares trading hands. Analyst Ratings Changes PGEN has been the […]
May 3, 2023
GERMANTOWN, Md., May 3, 2023 /PRNewswire/ -- Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,... | May 3, 2023
May 2, 2023
The Manufacturers Life Insurance Company boosted its holdings in shares of Precigen, Inc. (NASDAQ:PGEN – Get Rating) by 96.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,234 shares of the biotechnology company’s stock after purchasing an additional 21,269 shares […]
April 26, 2023
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...
April 17, 2023
– First preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR) – – MSLN is...
April 5, 2023
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT ... | April 5, 2023
April 3, 2023
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...